Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’

被引：0
|
作者：
Keisuke Imafuku
Koji Yoshino
Kei Yamaguchi
Satoshi Tsuboi
Kuniaki Ohara
Hiroo Hata
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center,Department of Dermatology
[2] Komagome Hospital,Department of Dermatology
[3] Hokkaido University Graduate School of Medicine,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e14 / e14
相关论文
共 50 条
  • [31] Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Maker, AV
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kannula, US
    Royal, RE
    Hughes, M
    Yellin, MJ
    Haworth, LR
    Levy, C
    Allen, T
    Mavroukakis, SA
    Attia, P
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2006, 29 (04) : 455 - 463
  • [32] Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
    Lee, Hansol
    Ferguson, Angela L.
    Quek, Camelia
    Vergara, Ismael A.
    daSilva, Ines Pires
    Allen, Ruth
    Gide, Tuba Nur
    Conway, Jordan W.
    Koufariotis, Lambros T.
    Hayward, Nicholas K.
    Waddell, Nicola
    Carlino, Matteo S.
    Menzies, Alexander M.
    Saw, Robyn P. M.
    Shklovskaya, Elena
    Rizos, Helen
    Lo, Serigne
    Scolyer, Richard A.
    V. Long, Georgina
    Palendira, Umaimaintha
    Wilmott, James S.
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2513 - 2524
  • [33] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [34] ANTI-CTLA-4 ANTIBODY THERAPY (IPILIMUMAB) INDUCED LUPUS-LIKE SKIN MANIFESTATIONS IN A METASTATIC MELANOMA PATIENT
    Calder, K.
    Armstrong, C.
    Hiatt, K.
    Smoller, B.
    Cheung, W.
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 93 - 93
  • [35] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [36] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    [J]. Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [37] Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.
    Wen, Xizhi
    Zhang, Xiaoshi
    Ding, Ya
    Li, Dandan
    Li, Jingjing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    [J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [39] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Kiniwa, Yukiko
    Kato, Hiroshi
    Yamasaki, Osamu
    Yoshikawa, Shusuke
    Maekawa, Takeo
    Matsushita, Shigeto
    Takenouchi, Tatsuya
    Inozume, Takashi
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Otsuka, Atsushi
    Fujimoto, Noriki
    Isei, Taiki
    Baba, Natsuki
    Matsuya, Taisuke
    Tanaka, Ryo
    Kaneko, Takahide
    Onishi, Masazumi
    Kuwatsuka, Yutaka
    Nagase, Kotaro
    Onuma, Takehiro
    Nomura, Motoo
    Umeda, Yoshiyasu
    Yamazaki, Naoya
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87
  • [40] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
    Azuma, Takeshi
    Takeuchi, Takumi
    Matayoshi, Yukihide
    Namiki, Shin
    Obara, Tetsuya
    Imamura, Kazuhiro
    Takamori, Mikio
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
12345